Corient Private Wealth LP Makes New Investment in Phreesia, Inc. $PHR

Corient Private Wealth LP bought a new stake in shares of Phreesia, Inc. (NYSE:PHR) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 120,380 shares of the company’s stock, valued at approximately $1,239,000.

A number of other large investors also recently added to or reduced their stakes in PHR. EverSource Wealth Advisors LLC lifted its holdings in shares of Phreesia by 1,119.8% in the first quarter. EverSource Wealth Advisors LLC now owns 3,269 shares of the company’s stock worth $27,000 after buying an additional 3,001 shares in the last quarter. Van ECK Associates Corp lifted its stake in Phreesia by 78.7% in the 4th quarter. Van ECK Associates Corp now owns 2,502 shares of the company’s stock worth $42,000 after purchasing an additional 1,102 shares in the last quarter. New York State Teachers Retirement System bought a new position in shares of Phreesia during the 1st quarter valued at about $44,000. Rockefeller Capital Management L.P. grew its position in shares of Phreesia by 354.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 2,755 shares of the company’s stock valued at $47,000 after purchasing an additional 2,149 shares in the last quarter. Finally, Allworth Financial LP purchased a new position in shares of Phreesia in the 2nd quarter worth approximately $58,000. 92.10% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Phreesia

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: RBC Capital reiterated a Buy rating on Phreesia, supporting the investment case despite recent earnings pressure. Phreesia Receives a Buy from RBC Capital
• Positive Sentiment: Royal Bank of Canada reaffirmed its Outperform rating and assigned a $19 price target, while Canaccord Genuity reaffirmed its Buy rating with a $16 target. The targets imply substantial upside from the recent trading level and indicate analysts remain confident in Phreesia’s longer-term prospects.
• Positive Sentiment: Second-quarter fiscal 2027 revenue increased approximately 10% year over year to $129.5 million, slightly exceeding consensus expectations. Adjusted EBITDA reached $32.9 million, highlighting continued operating profitability and scale. Phreesia Q2 Fiscal 2027 Revenue Rises 10 Percent
• Neutral Sentiment: Analyst commentary remains constructive, but the wide gap between current trading levels and price targets suggests the market is waiting for clearer evidence that Phreesia can accelerate earnings growth.
• Negative Sentiment: Phreesia reported quarterly EPS of $0.03, below the consensus estimate of $0.09. The earnings shortfall overshadowed the revenue beat and likely drove the negative investor reaction. Phreesia Shares Sink After 2Q Earnings Underwhelm

Phreesia Stock Performance

NYSE:PHR opened at $10.97 on Friday. The stock has a market capitalization of $678.08 million, a PE ratio of 64.53 and a beta of 0.86. The company has a fifty day moving average of $11.25 and a two-hundred day moving average of $10.47. Phreesia, Inc. has a fifty-two week low of $7.77 and a fifty-two week high of $30.43. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.76 and a current ratio of 1.76.

Phreesia (NYSE:PHR) last issued its quarterly earnings results on Wednesday, September 2nd. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.06). The firm had revenue of $129.46 million for the quarter, compared to analysts’ expectations of $129.06 million. Phreesia had a return on equity of 5.35% and a net margin of 2.06%.The firm’s revenue for the quarter was up 10.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.01 earnings per share. As a group, research analysts forecast that Phreesia, Inc. will post 0.39 earnings per share for the current fiscal year.

Analyst Ratings Changes

PHR has been the subject of several research reports. Barclays reissued an “equal weight” rating and issued a $10.00 price objective (down from $24.00) on shares of Phreesia in a research report on Thursday, May 14th. DA Davidson decreased their price objective on Phreesia from $14.00 to $13.00 and set a “buy” rating for the company in a report on Friday. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Phreesia in a research note on Thursday. Royal Bank Of Canada reiterated an “outperform” rating and set a $19.00 target price on shares of Phreesia in a report on Thursday. Finally, Piper Sandler downgraded shares of Phreesia from an “overweight” rating to a “neutral” rating and set a $12.00 target price on the stock. in a research report on Thursday, May 28th. Eight equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $15.25.

Phreesia Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.